- Home
- SKLZ vs ABOS Comparison
SKLZ vs ABOS Comparison
Compare SKLZ & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- ABOS
- Stock Information
- Founded
- SKLZ 2012
- ABOS 1996
- Country
- SKLZ United States
- ABOS United States
- Employees
- SKLZ N/A
- ABOS N/A
- Industry
- SKLZ EDP Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SKLZ Technology
- ABOS Health Care
- Exchange
- SKLZ Nasdaq
- ABOS Nasdaq
- Market Cap
- SKLZ 106.4M
- ABOS 90.3M
- IPO Year
- SKLZ N/A
- ABOS 2021
- Fundamental
- Price
- SKLZ $6.70
- ABOS $1.35
- Analyst Decision
- SKLZ Buy
- ABOS Strong Buy
- Analyst Count
- SKLZ 1
- ABOS 3
- Target Price
- SKLZ $15.00
- ABOS $6.33
- AVG Volume (30 Days)
- SKLZ 132.4K
- ABOS 588.6K
- Earning Date
- SKLZ 08-12-2025
- ABOS 08-12-2025
- Dividend Yield
- SKLZ N/A
- ABOS N/A
- EPS Growth
- SKLZ N/A
- ABOS N/A
- EPS
- SKLZ N/A
- ABOS N/A
- Revenue
- SKLZ $92,644,000.00
- ABOS N/A
- Revenue This Year
- SKLZ $0.20
- ABOS N/A
- Revenue Next Year
- SKLZ $14.10
- ABOS N/A
- P/E Ratio
- SKLZ N/A
- ABOS N/A
- Revenue Growth
- SKLZ N/A
- ABOS N/A
- 52 Week Low
- SKLZ $3.54
- ABOS $0.86
- 52 Week High
- SKLZ $9.06
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- SKLZ 43.47
- ABOS 48.03
- Support Level
- SKLZ $7.51
- ABOS $1.35
- Resistance Level
- SKLZ $8.65
- ABOS $1.60
- Average True Range (ATR)
- SKLZ 0.56
- ABOS 0.13
- MACD
- SKLZ -0.12
- ABOS -0.03
- Stochastic Oscillator
- SKLZ 4.84
- ABOS 17.31
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.